Results 191 to 200 of about 224,938 (296)

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The fibrosis‐4 (FIB‐4) score is used to identify risk of advanced liver fibrosis. This post hoc analysis investigated its prognostic value for cardiovascular (CV) outcomes and its relevance to the effects of dapagliflozin. Materials and Methods DECLARE‐TIMI 58 was a randomised, placebo‐controlled phase 3 trial investigating dapagliflozin ...
Jan Oscarsson, Monika Huhn, Yunyun Jiang, Ingrid Gause‐Nilsson, Stephen D. Wiviott, Filipe A. Moura, John P. H. Wilding, Simona Cernea, Luc Van Gaal, Avivit Cahn, Deepak L. Bhatt, Peter A. Johansson, C. David Sjöström   +12 more
wiley   +1 more source

GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers. [PDF]

Ann Med
Chikatimalla R, Shah A, Shah T, Perry G, Banker H, Aggarwal K, Jain R.   +6 more
europepmc   +1 more source

Ozone levels, changes and trends over Ireland: an integrated analysis [PDF]

, 2010
Colman, Liz, Jennings, S. Gerard, Lambkin, Keith, Moran, Eoin, O’Dowd, Colin, Tripathi, Om P.   +5 more
core  

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Evidence on cardiovascular/renal outcomes associated with GLP‐1‐based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP‐1‐based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and hypoglycemia risk, in adults with T1D in a large real‐world cohort.
Anastasios Tentolouris, Charalampos Filippatos, Nikolaos‐Iason Tepetes, Maria Gavriatopoulou, Evangelos Terpos, Alexandros Briasoulis, Kimon Stamatelopoulos, Theodosios Filippatos   +7 more
wiley   +1 more source

Low-Dose Aspirin for Cardiovascular Disease Primary Prevention in Patients With Giant Cell Arteritis.

JAMA Netw Open
Beydon M, Hajage D, Guédon AF, Carrat F, Seror R, Tubach F.   +5 more
europepmc   +1 more source

Retrospective real-world database study to examine the prevalence and incidence of cardiovascular diseases and medication prescription in Japanese patients with type 2 diabetes. [PDF]

Diabetol Int
Komatsu M, Kobayashi H, Tsuboi S, Watada H.   +3 more
europepmc   +1 more source

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

Prognostic value of serum gasdermin D in predicting major adverse cardiovascular events in patients with unstable angina: a prospective observational study. [PDF]

BMC Cardiovasc Disord
Wu L, Zhou Z, Yang X, Wu Q, Tan W.
europepmc   +1 more source

Two decades of biologic and JAK inhibitor prescription patterns in the western region of Melbourne

Internal Medicine Journal, EarlyView.
Abstract Background and Aim Safety concerns and medication shortages may influence prescribing practices in rheumatology. This study aimed to explore the impact of Janus kinase inhibitor (JAKi) safety warnings and the COVID‐19 pandemic on biologic and targeted‐synthetic disease‐modifying antirheumatic drug (b/tsDMARD) prescription patterns from 2002 to
Alexander Kwan, Elvina Ingrid, Sara Vogrin, Ken Luong, Fei Jin, Emma Brown, Dongzhe Li, Matthew Jiang, Keith K. T. Lim   +8 more
wiley   +1 more source

Secondary Hypogonadism and Effects of Testosterone Replacement Therapy on Cardiovascular Events.

J Clin Endocrinol Metab
Munro V, Law J, Matheson K, Imran SA.
europepmc   +1 more source